Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
meeting symbols : Teva save search
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
Published: 2024-04-16 (Crawled : 13:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 0.23%
H: 0.23%
C: -1.28%
austedo for meeting
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
Published: 2024-02-20 (Crawled : 15:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 2.72%
H: 0.0%
C: -0.8%
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 1.31%
H: 0.67%
C: -0.91%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 2.53%
H: 0.0%
C: 0.0%
antibody meeting teva
Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting
Published: 2023-04-11 (Crawled : 14:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 1.28%
H: 0.58%
C: -0.63%
austedo meeting teva
Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting
Published: 2023-02-24 (Crawled : 21:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -1.2%
H: 1.11%
C: 0.2%
digihaler system immunology meeting teva study
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting
Published: 2022-06-09 (Crawled : 18:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: -3.65%
ajovy injection
Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting
Published: 2022-05-23 (Crawled : 13:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 0.94%
H: 0.93%
C: -1.29%
austedo
Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting
Published: 2022-05-17 (Crawled : 12:20) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 4.77%
H: 4.8%
C: 3.32%
research
Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual Meeting
Published: 2022-04-01 (Crawled : 18:00) - biospace.com/
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 0.32%
H: 0.64%
C: -0.32%
ajovy injection
New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection Presented at 2021 American Headache Society (AHS) Annual Meeting
Published: 2021-06-03 (Crawled : 14:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -0.47%
H: 1.99%
C: 0.09%
injection
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2021 American Headache Society (AHS) Annual Meeting, Showcasing Teva’s Longstanding Heritage in the Management of Migraine
Published: 2021-06-03 (Crawled : 13:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -0.47%
H: 1.99%
C: 0.09%
migraine test injection
Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Association Annual Meeting
Published: 2021-05-03 (Crawled : 13:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 0.47%
H: 1.21%
C: 0.56%
Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia Clinical Outcomes at Upcoming 2021 American Psychiatric Association Annual Meeting
Published: 2021-04-27 (Crawled : 13:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -1.98%
H: 0.29%
C: -0.29%
schizophrenia
New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection and Reduction of Migraine Burden Presented at 2021 American Academy of Neurology Virtual Annual Meeting
Published: 2021-04-19 (Crawled : 13:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 0.19%
H: 0.05%
C: -4.55%
migraine injection ev
Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at Upcoming 2021 American Academy of Neurology Virtual Annual Meeting
Published: 2021-04-15 (Crawled : 13:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -0.09%
H: 1.01%
C: -0.37%
injection
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.